Blinding is a crucial methodological practice used in clinical trials to prevent bias. In the context of cancer research, blinding involves concealing the treatment allocation from one or more parties involved in the trial. This practice ensures that the outcomes are not influenced by either the participants or the researchers' expectations or behaviors.
